GVHD - GRAFT-VERSUS-HOST DISEASE
Clinical trials for GVHD - GRAFT-VERSUS-HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GVHD - GRAFT-VERSUS-HOST DISEASE trials appear
Sign up with your email to follow new studies for GVHD - GRAFT-VERSUS-HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Three-Drug cocktail aims to tame transplant complications in blood cancer patients
Disease control Not yet recruitingThis trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could less chemo be better after stem cell transplants?
Disease control Not yet recruitingThis phase 3 trial tests whether a lower dose of the chemotherapy drug cyclophosphamide can reduce side effects after a half-matched stem cell transplant for blood cancers. The standard dose often causes complications, so researchers want to see if a lower dose works just as well…
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Stem cell combo shows promise for deadly transplant complication
Disease control Not yet recruitingThis Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. …
Matched conditions: GVHD - GRAFT-VERSUS-HOST DISEASE
Phase: PHASE3 • Sponsor: Mesoblast, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC